What is the prevalence of Holmes-Adie Syndrome?

Holmes-Adie Syndrome is a rare neurological disorder characterized by a tonically dilated pupil and diminished deep tendon reflexes, with an estimated prevalence that remains difficult to quantify due to its often benign and asymptomatic nature. While exact global numbers are unknown, it is widely classified as a rare condition that predominantly affects young to middle-aged adults, particularly women.

How common is Holmes-Adie Syndrome?

Holmes-Adie Syndrome is considered a rare disorder. Because many individuals experience only mild symptoms—or none at all—the condition is frequently underdiagnosed or misdiagnosed, leading to a lack of precise epidemiological data. While formal population-wide studies are limited, clinical observations suggest that Holmes-Adie Syndrome is significantly more common in females than in males, with a female-to-male ratio often cited as approximately 2.5:1 or 3:1.

What is the typical age of onset for Holmes-Adie Syndrome?

Most patients are diagnosed with Holmes-Adie Syndrome between the ages of 20 and 40. While it can occur in pediatric or older populations, it is rarely seen outside of this prime adult range. The DiseaseMaps.org community, which currently includes 53 people living with Holmes-Adie Syndrome, provides a vital real-world perspective on how this age of onset impacts daily life, career, and social interactions for those navigating the condition.

Are there geographic or demographic patterns?

There is no evidence to suggest that Holmes-Adie Syndrome is linked to specific ethnic groups or geographic regions. The condition appears to occur sporadically worldwide. Challenges in gathering accurate prevalence data for Holmes-Adie Syndrome include:

• Asymptomatic presentation: Many individuals do not seek medical attention because the pupillary changes do not impair their vision or quality of life.


• Diagnostic overshadowing: Symptoms are sometimes attributed to other autonomic nervous system disorders.


• Lack of mandatory reporting: As a non-fatal, chronic condition, it is not tracked in centralized national disease registries in most countries.

Next steps

• Consult a neuro-ophthalmologist to confirm the diagnosis of Holmes-Adie Syndrome through pharmacological testing.


• Connect with the 53 members at DiseaseMaps.org to share management strategies and experiences.


• Monitor for any changes in pupillary response or new neurological symptoms that may warrant further investigation.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Holmes-Adie Syndrome overview.


• Orphanet: Rare disease database entry for Adie Syndrome.


• PubMed/NCBI: Clinical reviews on the epidemiology and autonomic features of Adie tonic pupil.


• OMIM (Online Mendelian Inheritance in Man): Clinical synopsis of Adie Syndrome.